[15, 16] However, data are limited on other disease outcomes for individuals who acquire HIV infection while receiving PrEP.[1–5, 9, 10, 17] Investigations in animal models have demonstrated lower peak viremia and lack of CD4+ T cell depletion in acute infection in SHIV challenged macaques that acquired infection while on intermittent oral tenofovir PrEP, but the applicability of this model for understanding the outcomes of human infection with HIV with PrEP use may be limited.[18]. This evidence concerns the gene CD4 and HIV infectious disease.